Total Immuno-Oncology Market in 7 MM to Reach USD 34 Bn in 2024, States GlobalData in Its Report Published at MarketPublishers.com
08 Aug 2016 • by Natalie Aster
LONDON – Worldwide, the immuno-oncology (IO) sector is anticipated to be estimated at around USD 14 billion by 2019, and reach the USD 34 billion market by 2024 the leading countries like the USA, France, Italy, Germany, the UK, Spain and Japan. The major factors propeling the growth of the market are likely to come from a upsurge in sales of immune checkpoint inhibitors reaching nearly USD 10 billion by 2019 and amounting to USD 24 billion by end-2024. IO drugs Opdivo and Keytruda are anticipated to account for the lion’s share of the total sales; the sales of these PD-1 inhibitors are projected to reach around USD 10 billion and USD 7 billion, respectively, by 2024. The 2 drugs are projected to be first-to-market in a slew of indications, being one jump ahead of such competitors as AstraZeneca’s durvalumab and Roche’s atezolizumab.
Non-small cell lung cancer (NSCLC), myeloma and melanoma are projected to have the largest contributions to the total IO market in 2019 and by 2024-end.
Novel combinations are likely to help late-to-market entrants like durvalumab attain huge sales.
Topical research report “Immuno-Oncology Strategic Insight - Multi-Indication And Market Size Analysis” created by GlobalData gives an exhaustive analysis and forecast of the IO therapeutics universe. It gives an all-round assessment of IO approaches, comprising checkpoint inhibitors, peptide vaccines, cell therapies, oncolytic viruses, CAR-T therapies and bi-specific antibodies. The study offers an analysis of the revenue based on indications for key IO products. It also offers a strategic competitor analysis; limelights key trends shaping and fuelling the market; provides market characterization; reviews novel technologies and products; casts light on major unmet needs; and provides clinical research mapping and implications for the market. The report presents a detailed pipeline analysis offering comprehensive data broken down across various stages, emerging new trends under development, and a granular evaluation of late-stage pipeline drug products. Furthermore, the study examines the competitive scenario and analyses the performance of diverse competitors.
More research reports by the publisher can be found at GlobalData page.